Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal.

Autor: Li X; Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China.; Institute for Drug Evaluation, Peking University Health Science Center, Beijing, 100191, China.; Therapeutic Drug Monitoring and Clinical Toxicology Center, Peking University, Beijing, 100191, China.; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China., Song Z; Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China.; Institute for Drug Evaluation, Peking University Health Science Center, Beijing, 100191, China.; Therapeutic Drug Monitoring and Clinical Toxicology Center, Peking University, Beijing, 100191, China., Chen Y; Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China.; Institute for Drug Evaluation, Peking University Health Science Center, Beijing, 100191, China.; Therapeutic Drug Monitoring and Clinical Toxicology Center, Peking University, Beijing, 100191, China.; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China., Wu J; Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China.; Institute for Drug Evaluation, Peking University Health Science Center, Beijing, 100191, China.; Therapeutic Drug Monitoring and Clinical Toxicology Center, Peking University, Beijing, 100191, China.; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China., Jiang D; Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China.; Institute for Drug Evaluation, Peking University Health Science Center, Beijing, 100191, China.; Therapeutic Drug Monitoring and Clinical Toxicology Center, Peking University, Beijing, 100191, China.; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China., Zhang Z; Sentum Health, Beijing, 100163, China., Wang Z; Sentum Health, Beijing, 100163, China. wangzeyuan@sentumhealth.com.; The University of Sydney, Sydney, Australia. wangzeyuan@sentumhealth.com., Zhao R; Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China. zhaorongsheng@bjmu.edu.cn.; Institute for Drug Evaluation, Peking University Health Science Center, Beijing, 100191, China. zhaorongsheng@bjmu.edu.cn.; Therapeutic Drug Monitoring and Clinical Toxicology Center, Peking University, Beijing, 100191, China. zhaorongsheng@bjmu.edu.cn.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Nov 02; Vol. 74 (1), pp. 2. Date of Electronic Publication: 2024 Nov 02.

Effects of combined radiotherapy with immune checkpoint blockade on immunological memory in luminal-like subtype murine bladder cancer model.

Autor: Huang J; Cancer Research Program, Research Institute of McGill University Health Center, Montréal, QC, Canada., Michaud E; Cancer Research Program, Research Institute of McGill University Health Center, Montréal, QC, Canada., Shinde-Jadhav S; Cancer Research Program, Research Institute of McGill University Health Center, Montréal, QC, Canada., Fehric S; Cancer Research Program, Research Institute of McGill University Health Center, Montréal, QC, Canada., Marcq G; Division of Urology, Department of Surgery, McGill University Health Center, Montréal, QC, Canada., Mansure JJ; Cancer Research Program, Research Institute of McGill University Health Center, Montréal, QC, Canada., Cury F; Department of Radiation Oncology, McGill University Health Center, Montréal, QC, Canada., Brimo F; Department of Pathology, McGill University Health Center, Montréal, QC, Canada., Piccirillo CA; Department of Microbiology and Immunology, McGill University, Montréal, QC, Canada.; Infectious Diseases and Immunology in Global Health Program, The Research Institute of the McGill University Health Centre (RI-MUHC), Montréal, QC, Canada.; Centre of Excellence in Translational Immunology, Montréal, QC, Canada., Kassouf W; Cancer Research Program, Research Institute of McGill University Health Center, Montréal, QC, Canada.; Division of Urology, Department of Surgery, McGill University Health Center, Montréal, QC, Canada.; Centre of Excellence in Translational Immunology, Montréal, QC, Canada.

Publikováno v: Cancer biology & therapy [Cancer Biol Ther] 2024 Dec 31; Vol. 25 (1), pp. 2365452. Date of Electronic Publication: 2024 Jun 11.

Insight of immune checkpoint inhibitor related myocarditis.

Autor: Pi JK; Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China., Chen XT; Animal Experimental Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China., Zhang YJ; Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China., Chen XM; Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China., Wang YC; Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China., Xu JY; Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China., Zhou JH; Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China., Yu SS; Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China., Wu SS; Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China. Electronic address: wusisi@wchscu.cn.

Publikováno v: International immunopharmacology [Int Immunopharmacol] 2024 Dec 25; Vol. 143 (Pt 3), pp. 113559. Date of Electronic Publication: 2024 Nov 12.

A comprehensive review of immune checkpoint inhibitors for cancer treatment.

Autor: Arafat Hossain M; Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh. Electronic address: mdarafathossain745@gmail.com.

Publikováno v: International immunopharmacology [Int Immunopharmacol] 2024 Dec 25; Vol. 143 (Pt 2), pp. 113365. Date of Electronic Publication: 2024 Oct 23.

Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial.

Autor: Ma LX; Princess Margaret Cancer Centre, Toronto, Ontario, Canada lucy.ma@uhn.ca., Titmuss E; BC Cancer - Vancouver, Vancouver, British Columbia, Canada., Loree JM; BC Cancer - Vancouver, Vancouver, British Columbia, Canada., Jonker DJ; The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Kennecke HF; Providence Cancer Center, Portland, Oregon, USA., Berry S; Trillium Health Partners, Mississauga, Ontario, Canada., Couture F; Centre de recherche de l'Hotel-Dieu de Quebec, Quebec, Canada, Canada., Ahmad CE; Eastern Health, St. John's, Newfoundland and Labrador, Canada., Goffin JR; Juravinski Cancer Centre, Hamilton, Ontario, Canada., Kavan P; Segal Cancer Centre, Montreal, Quebec, Canada., Harb M; Moncton Hospital, Moncton, New Brunswick, Canada., Colwell B; Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada., Samimi S; Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada., Samson B; Hopital Charles-Lemoyne, Greenfield Park, Quebec, Canada., Abbas T; Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada., Aucoin N; Hopital de la Cite-de-la-Sante, Laval, Quebec, Canada., Aubin F; Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada., Koski S; Cross Cancer Institute, Edmonton, Alberta, Canada., Tu D; Canadian Cancer Trials Group, Kingston, Ontario, Canada., O'Callaghan C; Canadian Cancer Trials Group, Kingston, Ontario, Canada.; Public Health Sciences, Queen's University, Kingston, New York, Canada., Chen EX; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Dec 04; Vol. 12 (12). Date of Electronic Publication: 2024 Dec 04.